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SUMMARY 
Background: Depression around the time of pregnancy affects at least 1 in 8 women and 
treatment with selective serotonin re-uptake inhibitors (SSRIs) in pregnant women has been 
increasing, but research on adverse effects on the fetus have so far commonly used designs 
unable to account for confounding. We aimed to examine the effects of prenatal SSRI exposure 
on offspring size outcomes and gestational age, and disentangle whether associations observed 
were due to the medication or other factors. 
 
Methods: We used a Swedish population-based cohort of 392,029 children and national 
registers to estimate the associations between prenatal exposure to SSRIs and depression on the 
outcomes birth weight, birth length, birth head circumference, gestational age at birth, and 
preterm birth. A sub-sample of 1007 children was analyzed in a within-family design that 
accounts for unmeasured parental genetic and environmental confounds. 
 
Results: Crude analyses revealed associations between prenatal SSRI exposure and offspring 
birth size, and gestational age. However, in the within-family analyses, only the association 
between SSRI exposure and reduced gestational age (-2.3 days; 95% CI -3.8 to -0.8) was 
observed. 
 
Conclusions: This study indicates that prenatal SSRI exposure may not be causally related to 
offspring birth size. Rather, our analyses suggest that the association could be caused by other 
underlying differences instead of the medication per se. A small reduction of gestational age was 
associated with SSRI exposure in the within-family analysis and could be due to either the 
exposure, or other factors changing between pregnancies. 
Keywords: Depression, medication, pregnancy, antidepressants, pharmacoepidemiology 
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INTRODUCTION 
Major depressive disorder, a common psychiatric disorder characterized by persistent depressed 
mood with both cognitive and physiological symptoms, is expected to be the second leading 
cause of disability worldwide by 2020.1-4 Estimates show that at least 1 in 8 women suffers from 
perinatal depression, making the time around pregnancy a high-risk period for substantial 
morbidity, mortality, and personal and societal costs.5-10 Treating depressed pregnant women is 
imperative because depression can also confer risk of suicidal or infanticidal ideation.11 Selective 
serotonin re-uptake inhibitors (SSRIs) are frequently used to treat depression, and the 
prescriptions of these drugs have increased both in general,12 and among pregnant women.13, 14 
Treatment with SSRIs is considered both efficacious and well tolerated by patients,15 but less is 
known about possible adverse effects on the unborn fetus. 
Studies have reported smaller head size in mice prenatally exposed to SSRIs,16 and in serotonin 
transporter knockout mice; the corresponding high levels of serotonin is thought to cause 
abnormal wiring of the somatosensory cortex and the lateral geniculate nucleus in the brain.17 In 
humans, studies have shown that antidepressants pass the placenta, and ratios between 0.29 and 
0.89 of the maternal serum levels of antidepressants and their metabolites can be detected in 
umbilical cord blood, with the highest ratio reported for the SSRI citalopram.18 Further, studies 
in humans have reported associations between prenatal SSRI exposure and preterm birth,19-21 
persistent pulmonary hypertension,22, 23 septal heart defects,24 lower birth weight,21, 25 lower 
gestational age,19, 25 malformations at birth,26  fetal death,21 and reduced fetal head growth.27 
 
Research has shown that women suffering from depression during pregnancy are frequently 
missed by the healthcare.28 With better understanding, screening, and treatment of depression 
around the time of pregnancy, the use of SSRIs among pregnant women can be expected to 
increase even further. It is, therefore, of high importance to further study the possible adverse 
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effects on children exposed to SSRIs during pregnancy. However, due to safety reasons, the 
effects of medication exposure on unborn children are not studied in randomized settings29 
leading studies on adverse effects of medication in pregnant women to rely on observational 
data. One major obstacle in observational studies is confounding, and in 
pharmacoepidemiological studies specifically confounding by indication or confounding by 
broader underlying factors affecting both the indication and subsequent medication. Medicated 
and non-medicated individuals will have different underlying risks for the factors that caused the 
treatment, and these underlying differences may, wholly or partially, explain an observed 
difference in the outcome studied. In this case, it could be the case that women with depression 
(or liability for depression) have an increased risk for adverse pregnancy outcomes, which may 
account for the previously found associations between SSRI and adverse pregnancy outcomes. 
One way of addressing this issue would be to use within-family designs that can account for 
familial liability.30 
 
In this study, we estimated the effects of prenatal exposure to SSRIs on birth weight, birth 
length, birth head circumference, gestational age at delivery, and preterm birth. We first used a 
population-based cohort of almost 400,000 Swedish children in an ordinary epidemiological 
analysis controlling for a number of confounding factors. We then used a sub-sample of the 
cohort in a within-family design that controlled for all environmental factors affecting the 
parents prior to the pregnancy of the first child, the mother's and father's genetic makeup, 
maternal factors consistent between the births, the children’s genetic makeup, and all other 
covariates that did not change between the births of the children.  
 
METHODS 
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Study population 
We used the Swedish personal identification number to link national Swedish registers with high 
accuracy.31 The Swedish Medical Birth Register (MBR) covers 99% of all births since 1973,32 
and was used to create a population-based cohort (N=392,029) consisting of all children born 
between April 1st 2006 and December 31st 2009. Stillborn births and twin births were excluded. 
Using the birthdate and information on gestational age at birth, provided in the MBR, we could 
calculate date of conception. 
The cohort was further linked to the Multi-Generation Register (MGR) that contains information 
on first-degree relatives for persons born 1932 and later.33 The MGR was used to identify both 
parents and consequently the relatedness of the children. In total, a within-family sub-sample of 
1007 full siblings where the siblings had different prenatal SSRI exposure was identified.  
Exposures 
SSRIs during pregnancy 
Medication with SSRIs was determined by linking the mothers to the Swedish Prescribed Drug 
Register. The register contains information on all prescribed and dispensed prescription drugs 
since July 1st 2005,34 including the name of the drug, prescription- and dispensation dates, and a 
code in accordance with the Anatomical Therapeutic Chemical Classification System (ATC). We 
identified dispensations of SSRI medication around the time of pregnancy using ATC codes 
under the category N06AB (SSRIs), and defined a binary exposure variable (1: no dispensations 
from three weeks before pregnancy until the childbirth (no SSRI exposure). 2: more than one 
dispensation between conception and childbirth, or one dispensation within the pregnancy period 
and at least one more dispensation within 6 months before or after the dispensation during 
pregnancy (SSRI exposure). 
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Depression diagnosis 
The National Patient Register, providing information on Swedish psychiatric inpatient and 
outpatient care,35 was used to identify treatment contacts for depression. The register contains 
dates along with the main discharge diagnosis code, and up to eight secondary diagnosis codes in 
accordance with the International Classification of Disease (ICD). Depression was defined as at 
least one treatment contact for depression (ICD-10 F32.0/.1/.2/.3/.8/.9, F33.0/.1/.2/.3/.4/.8/.9, 
F34.1, F41.2) between conception and delivery. It should be noted that this diagnosis might not 
reflect an on-going depression, but could be part of a planned follow-up visit from a previous 
depressive episode. 
Exposure categories 
A categorical exposure variable was created based on SSRI medication and hospital care for 
depression (0: No SSRI exposure, and no hospital care for depression during pregnancy. 1: SSRI 
exposure. 2: At least one treatment contact for depression during pregnancy, and no SSRI 
medication).  
Outcomes 
In Sweden, a newborn child is routinely measured and weighted at birth and the information is 
recorded in the MBR. Gestational age at birth, also in the MBR, is calculated through 
standardized ultrasound measurements at pregnancy week 16-18. We used birth weight (grams), 
birth length (cm), birth head circumference (cm), gestational age at delivery (days), and preterm 
birth (gestational age at birth <259 days) as outcomes. 
The birth size measurements of the child will depend on the gestational age at birth, and 
therefore the growth outcomes were standardized by gestational age at birth. Birth weight, birth 
length, and birth head circumference were standardized by gestational age at birth using the 
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mean and standard deviation of children in the cohort born within the same gestational week. 
The standardized values of birth weight displayed a correlation of 0.98 with a previous method 
based on ultrasound measurements at different gestational ages during pregnancy in healthy 
children.36  
Covariates 
We adjusted for several factors that might confound the associations. The BMI of the mother 
was calculated (weight in kilograms divided by height in meters squared) based on weight and 
length measured at the first antenatal care visit (from the MBR), and divided into four categories 
(<18.5, 18.5-25, 25-30, >30). The height of the mother was also used as a separate covariate. The 
birth order was also included from the MBR as there might be systematical differences for using 
SSRI depending on the mother's parity at the specific pregnancy. Previous psychiatric history 
was ascertained using any hospital contact with a psychiatric diagnosis from the NPR prior the 
specific childbirth using ICD 7th-10th revisions. The mother's age at delivery (years), and 
smoking status (1: does not smoke. 2: 1-9 cigarettes per day. 3: >9 cigarettes per day) at first 
antenatal care visit, was obtained from the MBR. The highest completed education (1: 
compulsory school. 2: upper secondary school. 3: post secondary education less than three years. 
4: university three years or more) the year of delivery was obtained by linking the subjects to the 
Swedish longitudinal integration database for health insurance and labour market studies. 
Statistical methods 
In the population analyses, the association between prenatal exposure of SSRI medication, or 
depression without SSRI medication, and the continuous variables birth weight, birth length, 
birth head circumference, and gestational age at birth were estimated by linear regression 
analyses, while the binary preterm birth outcome was analyzed by logistic regression. The 
children not exposed to depression or SSRI was used as the reference group and the analyses 
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adjusted for all the covariates. Robust standard errors were used, as several children from the 
same mother were included in the analysis. 
The within-family analyses were done by estimating models with a fixed effects regression 
estimator (xtreg statement, within mother) for continuous variables and conditional logistic 
regression for preterm birth. This design will automatically control for all covariates that did not 
change between the births. In these analyses we included all families with at least two siblings 
discordant for SSRI exposure, but if more than two siblings were identified they were also 
included. The children not exposed to depression or SSRI was used as the reference group. 
All analyses were performed in STATA/IC 13.1. 
RESULTS 
Population analyses 
See Table 1 for descriptive statistics of the cohort. We identified 392,029 children born between 
April 1st 2006 and December 31st 2009. During pregnancy, 6572 (1.7%) were exposed to SSRI, 
and 1625 (0.4%) children were exposed to a depressive mother not treated with an SSRI. 
Children born to mothers using SSRIs during pregnancy displayed lower birth length and smaller 
birth head circumference, shorter gestational age at birth, and a higher probability of preterm 
birth (Table 2). 
Within-family analyses 
By applying a within-family design one automatically control for a wide range of unmeasured 
confounding factors that are shared within the family but not possible to control for with 
population analyses. 
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Table 3 provides descriptive characteristics of the within-family sub-sample. From the initial 
cohort, we identified 496 women giving birth to more than one child with the same father and 
with children discordant for SSRI exposure. 
The associations between SSRI exposure and birth length, birth head circumference, and birth 
weight observed in the full cohort was all attenuated in the within-family analyses and no 
differences were observed (Table 2). 
Gestational age at delivery was lower (-2.27 days; 95% CI -3.79 to -0.75; P=0.004) in the group 
of children exposed to SSRI, and the odds ratio for preterm birth was similar as in the population 
cohort, although with confidence intervals overlapping zero (Table 2). 
One possibility is that this remaining difference is due to the depression underlying the 
medication and that women with a depression have a greater likelihood of shorter gestational 
age. We therefore compared children exposed to depression (without SSRI exposure during fetal 
life) with children of mothers without a diagnosis of depression or SSRI medication. As seen in 
Table 2 also these children had lower gestational age (-1.69; 95% CI -2.51 to -0.86; P<0.001) 
and higher probability of preterm birth (OR 1.31; 95% CI 1.07 to 1.60; P=0.009). 
 
DISCUSSION 
There is concern that SSRI-exposure influences fetal development.19-27 Similar to previous 
studies,21, 25, 27 we observed lower birth length and birth head circumference in children where 
the mother was medicated with an SSRI during the pregnancy when analyzing the total-
population cohort. However, when applying a within-family design where full siblings with 
different prenatal exposures of SSRIs were compared, consequently adjusting the analyses for 
unmeasured genetic and environmental factors shared by siblings, we observed no differences in 
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the estimates. While the group of children prenatally exposed to SSRIs in the population 
analyses indeed had lower birth size, findings from this study suggest that the offspring birth 
outcomes were likely not caused by the SSRI medication. Rather, the associations between the 
outcomes and SSRI exposure could be due to underlying factors causing both the SSRI 
medication of the mother and the lower birth size of the children. 
Lower gestational age and preterm birth have also been associated with prenatal SSRI exposure 
in previous studies.19-21, 25 We also observed an association between prenatal SSRI exposure and 
lower gestational age in our population analysis (-3.1 days). In contrast to the other pregnancy 
outcomes studied, an association was also observed in the within-family analysis (-2.3 days). An 
association between prenatal SSRI exposure and preterm birth was observed in the population 
sample, but in the within-family sample the confidence intervals overlapped zero. However, the 
estimates for preterm birth were similar using both methods. It is likely that the broader 
confidence intervals are due to power, as using a binary outcome variable reduces the number of 
informative sibling pairs. A within-family association between SSRI exposure during fetal life 
and gestational age and preterm birth could have several potential explanations. The association 
could be due to a causal effect of the SSRI. An alternative explanation would be that a 
depression underlying the medication is causing the association. A third possibility would be that 
the association is due to liability for depression. We tried to address these alternatives by 
comparing women having at least one treatment contact with a discharge diagnosis code for 
depression but no SSRI medication during pregnancy to women not having a treatment contact 
for depression or SSRI medication during pregnancy. First, note that a treatment contact with a 
discharge diagnosis code for depression might not reflect a current ongoing depressive episode 
but could rather be part of a planned follow up visit and that lack of SSRI medication could 
indicate that these women were either not depressed during pregnancy, or had a less severe 
depression. Yet, the analyses showed that women with a depression diagnosis during pregnancy 
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were more likely to have both shorter gestational age and preterm birth offspring compared to 
women without a treatment contact for depression or SSRI medication during pregnancy. If 
depression liability was the only factor influencing gestational age, no association should be 
observed in the within-family analyses. However, an association was observed, indicating 
influence from factors other than the liability, for example the SSRI medication, or the 
depression leading to the treatment. Regardless of which of the alternatives is most influential, 
we found no difference in any of the birth size outcomes in the within-family analyses. 
Therefore, the small reduction in gestational age observed in the prenatally SSRI exposed child, 
compared to a non-exposed full sibling, does not seem to be correlated with impaired growth. 
Our study focused on a finite number of outcomes and therefore cannot reject or replicate any 
studies focusing on the association between prenatal SSRI exposure and other outcomes. 
However, our study shows that confounding factors play a major role in the complex relationship 
between pharmacological treatment of pregnant women and adverse pregnancy outcomes. 
Observational studies of prenatal drug exposure not using a genetically-informed design are at 
risk of drawing incorrect conclusions regarding the causality of associations observed in the 
population. 
This study has several strengths, including the large population-based cohort of mothers and 
children linked to Swedish nation-wide registers and a healthcare system with equal access. The 
study used standardized growth outcomes that had been adjusted for gestational age at birth. 
Further, the additional within-family analyses allowed controlling for unmeasured confounding 
factors that full-cohort analyses cannot, and could thereby provide better understanding of the 
causality of the observed associations. 
This study uses prescription and pharmacy dispensation data, but the adherence to the prescribed 
treatment is unknown and is a limitation. Furthermore, the Swedish National Patient Register 
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used to identify treatment contacts for depression does not include information from primary 
care. Consequently, identified depressed mothers without SSRI treatment will be on the more 
severe end of the depressive spectrum as they have received treatment in a specialist care setting. 
This might explain the low numbers of mothers with depression lacking SSRI medication. The 
absence of primary care data will also lead mothers without SSRI medication and primary care 
only to be classified as unexposed. However, potentially mis-classified mothers only make up a 
very small portion of the unexposed group. Further, the sub-sample of families used in the 
within-family analysis required at least two full siblings. The study only included children born 
between April 1st 2006 and December 31st 2009, and by giving birth to more than one child 
within this time frame, the mothers in the within-family sub-sample could differ from the general 
population. Additionally, a sibling design is not free from potential bias, and the design could 
oversample measurement errors. Further, while a family approach allows adjustment for the 
parent’s genetics, environmental exposures prior the pregnancy of the first child, and factors 
consistent between pregnancies, the sibling design become very unbalanced when exposures and 
outcomes changes over time and parity or calendar time adjustments will not adjust for changes 
in exposures related to the outcome of previous births.37 For example, a within family analysis 
does not adjust for changes in behavior as a consequence of perceived consequences of 
exposure. That might be the case if a first pregnancy is exposed and results in e.g. low 
gestational age, and that results in both changes in exposure and relevant behavior. If this type of 
bias is present, the small association between prenatal SSRI exposure and reduced gestational 
age might be an overestimate.  
 
In conclusion, this study indicates that prenatal SSRI exposure may not be causally related to 
offspring birth size. Rather, our analyses suggests that associations between prenatal SSRI 
exposure and the studied offspring size outcomes may be due to other factors, including the 
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underlying depression or different characteristics of women taking SSRI during pregnancy 
compared to women with a lower liability for depression. This study did find an association 
between SSRI exposure and reduced gestational age in both the population analysis, and in the 
within-family analysis. However, this reduction of gestational age was small (-2.3 days) and 
could be due to the exposure of the antidepressant, or due to factors changing between the 
pregnancies compared. In addition to provide further information for the clinical decision 
whether to prescribe SSRIs or not during a pregnancy, our study highlights the strong presence 
of confounding factors in pharmacoepidemiological studies.  
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KEY MESSAGES 
 Maternal depression around the time of pregnancy is not uncommon and antidepressant 
medication prescriptions have increased both in the general population and among 
pregnant women. 
 When comparing children prenatally exposed to SSRI or to a depressed mother without 
SSRI treatment, crude analyses revealed associations with lower birth size and 
gestational age, as well as increased odds ratios for preterm birth.  
 Within-family analyses of full siblings with different exposure to SSRI did not reveal 
associations between prenatal SSRI exposure and birth size. However, the association 
with lower gestational age was still observed, but did not seem to have a strong effect on 
growth. 
 This indicates that the associations with birth size, seen in the crude analyses, could be 
due to underlying confounding factors such as parental genetic or environmental factors 
rather than the medication per se. 
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